Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

dm Clinical Trial

Official title:

Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03925701
• Other study ID #: diabetes mellitus tanta
• Status: Recruiting
• Phase: Phase 3
• Start date: April 1, 2019
• Est. completion date: December 2028

Study information

• Verified date: April 2019
• Source: Tanta University
• Contact: Sherief Abd-Elsalam, ass. prof.
• Phone: 00201147773440
• Email: sheriefabdelsalam[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical study evaluating vildagliptin versus vildagliptin/metformin on NAFLD with DM.

Description:

Clinical study evaluating vildagliptin versus vildagliptin/metformin on nonalcoholic fatty liver disease with DM.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 2028
• Est. primary completion date: December 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• NAFLD and type 2 DM

Exclusion Criteria:

• Viral hepatitis.

• Child score more than 6.

• renal impairment.

Related Conditions & MeSH terms

• dm

Intervention

Drug:
• Vildagliptin
vildagliptin twice daily
• vildagliptin\metformin
vildagliptin\metformin twice daily

Locations

Country	Name	City	State
Egypt	Tanta University	Tanta

Sponsors (1)

Lead Sponsor	Collaborator
Sherief Abd-Elsalam

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of patients with improved nafld and insulin resistance	number of patients showing improved nafld and insulin resistance	6 months